FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385666988> ?p ?o ?g. }

• W4385666988 endingPage "e51929aa" @default.
• W4385666988 startingPage "e51929aa" @default.
• W4385666988 abstract "Topic: 22. Stem cell transplantation - Clinical Background: Leukemia risk stratification guides treatment. Recently, ELN 2022 risk stratification was released, with some changes from the previous ELN 2017. There are few reports of stratification based on ELN 2022, and the applicability of the new stratification needs to be confirmed by large queues. At present, allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is the only way to cure acute myeloid leukemia (AML). It remains to be seen whether ELN2022 can indicate transplant prognosis. Aims: Re-classify from the ELN 2017 to ELN 2022: distribution and outcomes of SCT Compare the prognostic value of ELN 2017 and 2022 risk classifications in transplantation Methods: We enrolled 765 adult AML patients from January 2014 to December 2021 at Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and patients were diagnosed according to the 2017 WHO definition. 600 patients were included in our study excluding patients with APL, autologous transplantation, incomplete cytogenetic data at initial diagnosis, and lost follow-up (Figure 1). NGS panel targeted 137 genes encompassing mutations referred to ELN 2022 and 2017. High-throughput gene sequencing was performed by ultra-high multiplex PCR exon enrichment, with an average sequencing depth of 800×, Ion Mutation analysis was performed using dbSNP, 1000 Genomes, Polyphen-2, and COSM. Polyphen-2 and COSMIC databases for mutation annotation and amino acid mutation analysis. The detection rate was 97%-98%. FLI3-ITD was simultaneously detected by PCR; NPM1-Exon12, CEBPA- TAD, NPM1-Exon12, CEBPA- TAD, CEBPABZIP, CALR-EXON9, and MPL-Exon10 were detected by Sanger sequencing. Results: •Re-stratification from the ELN 2017 to ELN 2022 classifications Compared with the 2017 ELN risk category, there are 4.36% of patients had a reduced risk category, 8.37% had an increased risk category and 80.38% had an equal risk stratification by the 2022 ELN risk category (Figure 2). •Clinical characteristics of AML patients according to the 2022 ELN classification Characteristics of 600 patients were seen in Table 1. The 5-year OS of favorable, intermediate, adverse groups according to 2022 ELN was 65.8% (95% CI 57.9%~74.7%), 56(95% CI 47.2%~66.5%), and 49.0% (95% CI 40.6%~59.1%) respectively (P=0.039). However, according to ELN 2017, the 5-year OS of favoralbe, intermediate, adverse groups was 64.3% (95% CI 55.8%~74.2%), 61% (95% CI 53%~70.4%), and 49.1% (95% CI 39.4%~61.3%) (P=0.035). •To evaluate the value of ELN 2022 and ELN 2017 for allo-HSCT prognosis, we performed a multiple cox model to calculate the AUC value which showed 66.8% and 68.1% respectively. Summary/Conclusion: Our study showed a single-center outcome of allo-HSCT for adult AML patients from China. ELN 2022 did not show greater survival differences between the unfavorable and intermediate group than ELN 2017. ELN2022 and ELN2017 may both not be appropriate risk systems for predicting allo-HSCT outcomes.Figure 2 Shift of re-stratification from the ELN 2017 to ELN 2022 classifications.a b Figure 3 OS and DFS according to 2022 ELN risk classification Figure 4. ELN 2022 predicts OS of AML patients with allo-HSCT (a); ELN 2017 predicts OS of AML patients with allo-HSCT (a)Keywords: Acute myeloid leukemia, ELN, Allogeneic stem cell transplant" @default.
• W4385666988 created "2023-08-09" @default.
• W4385666988 creator A5010126010 @default.
• W4385666988 creator A5029862222 @default.
• W4385666988 date "2023-08-01" @default.
• W4385666988 modified "2023-09-27" @default.
• W4385666988 title "P1280: COMPARING TRANSPLANT OUTCOMES OF AML PATIENTS FOR 2017 AND 2022 ELN RISK STRATIFICATION: A REAL-WORLD STUDY FROM A SINGLE CENTER IN CHINA" @default.
• W4385666988 doi "https://doi.org/10.1097/01.hs9.0000972008.51929.aa" @default.
• W4385666988 hasPublicationYear "2023" @default.
• W4385666988 type Work @default.
• W4385666988 citedByCount "0" @default.
• W4385666988 crossrefType "journal-article" @default.
• W4385666988 hasAuthorship W4385666988A5010126010 @default.
• W4385666988 hasAuthorship W4385666988A5029862222 @default.
• W4385666988 hasBestOaLocation W43856669881 @default.
• W4385666988 hasConcept C104317684 @default.
• W4385666988 hasConcept C126322002 @default.
• W4385666988 hasConcept C143998085 @default.
• W4385666988 hasConcept C194409129 @default.
• W4385666988 hasConcept C2483381 @default.
• W4385666988 hasConcept C2777408962 @default.
• W4385666988 hasConcept C2778729363 @default.
• W4385666988 hasConcept C2911091166 @default.
• W4385666988 hasConcept C3020404979 @default.
• W4385666988 hasConcept C30481170 @default.
• W4385666988 hasConcept C45091340 @default.
• W4385666988 hasConcept C501734568 @default.
• W4385666988 hasConcept C53226629 @default.
• W4385666988 hasConcept C54355233 @default.
• W4385666988 hasConcept C71924100 @default.
• W4385666988 hasConcept C86803240 @default.
• W4385666988 hasConceptScore W4385666988C104317684 @default.
• W4385666988 hasConceptScore W4385666988C126322002 @default.
• W4385666988 hasConceptScore W4385666988C143998085 @default.
• W4385666988 hasConceptScore W4385666988C194409129 @default.
• W4385666988 hasConceptScore W4385666988C2483381 @default.
• W4385666988 hasConceptScore W4385666988C2777408962 @default.
• W4385666988 hasConceptScore W4385666988C2778729363 @default.
• W4385666988 hasConceptScore W4385666988C2911091166 @default.
• W4385666988 hasConceptScore W4385666988C3020404979 @default.
• W4385666988 hasConceptScore W4385666988C30481170 @default.
• W4385666988 hasConceptScore W4385666988C45091340 @default.
• W4385666988 hasConceptScore W4385666988C501734568 @default.
• W4385666988 hasConceptScore W4385666988C53226629 @default.
• W4385666988 hasConceptScore W4385666988C54355233 @default.
• W4385666988 hasConceptScore W4385666988C71924100 @default.
• W4385666988 hasConceptScore W4385666988C86803240 @default.
• W4385666988 hasIssue "S3" @default.
• W4385666988 hasLocation W43856669881 @default.
• W4385666988 hasLocation W43856669882 @default.
• W4385666988 hasOpenAccess W4385666988 @default.
• W4385666988 hasPrimaryLocation W43856669881 @default.
• W4385666988 hasRelatedWork W2106245425 @default.
• W4385666988 hasRelatedWork W2150690129 @default.
• W4385666988 hasRelatedWork W2157032869 @default.
• W4385666988 hasRelatedWork W2167468830 @default.
• W4385666988 hasRelatedWork W2193596267 @default.
• W4385666988 hasRelatedWork W2774443367 @default.
• W4385666988 hasRelatedWork W2781611671 @default.
• W4385666988 hasRelatedWork W3030821596 @default.
• W4385666988 hasRelatedWork W3138153931 @default.
• W4385666988 hasRelatedWork W4220922874 @default.
• W4385666988 hasVolume "7" @default.
• W4385666988 isParatext "false" @default.
• W4385666988 isRetracted "false" @default.
• W4385666988 workType "article" @default.